Drug-drug interaction software in clinical practice: A systematic review

European Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2015, Pages 131-142

  Roblek, Tina ^a,b   Vaupotic, Tomaz ^b   Mrhar, Ales ^a   Lainscak, Mitja ^a,c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Lek dd   (Slovenia)

^c General Hospital Celje   (Slovenia)

Author keywords

Clinical usefulness; Drug drug interaction screening software; Drug drug interactions; Systematic review

Indexed keywords

ADVERSE OUTCOME; ARTICLE; CANCER PATIENT; CLINICAL PRACTICE; COMPUTER PROGRAM; DATA BASE; DRUG INTERACTION; GERIATRIC PATIENT; HUMAN; PHARMACIST; PHYSICIAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; DRUG DATABASE;

DATABASES, PHARMACEUTICAL; DRUG INTERACTIONS; HUMANS; SOFTWARE;

EID: 84925485581     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1786-7     Document Type: Article

References (56)

1. Askari M, Eslami S, Louws M, Wierenga et al (2013) Frequency and nature of drug-drug interactions in the intensive care unit: frequency of DDIs in the ICU. Pharmacoepidemiol Drug Saf 22(4):430-437
2. Reis AMM, Cassiani SHDB (2010) Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci 32(6):822-828
3. Vonbach P, Dubied A, Krähenbühl S et al (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30(4):367-374
4. Böttiger Y, Laine K, Andersson ML et al (2009) SFINX - a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65(6):627-633
5. Andersson ML, Böttiger Y, Lindh JD et al (2012) Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol 69(3):565-571
6. Fournier J-P, Sommet A, Durrieu G et al (2014) Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. Fundam Clin Pharmacol 28(2):230-235
7. Leone R, Magro L, Moretti U et al (2010) Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf Int J Med Toxicol Drug Exp 33(8):667-675
8. Paterno MD, Maviglia SM, Gorman PN et al (2009) Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc 16(1):40-46
9. Peng CC, Glassman PA, Marks IR et al (2003) Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 9(6):513-522
10. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100
11. Langdorf MI, Fox JC, Marwah RS et al (2000) Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 7:1321-1329
12. Cruciol-Souza JM, Thomson JC (2006) A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clin São Paulo Braz 61(6):515-520
13. Straubhaar B, Krähenbühl S, Schlienger RG (2006) The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf 29(1):79-90
14. Rätz Bravo AE, Tchambaz L et al (2005) Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28(3):263-275
15. Bista D, Saha A, Mishra P et al (2009) Impact of educational intervention on the pattern and incidence of potential drug-drug interactions in Nepal. Pharm Pract 7(4):242-247
16. Secoli S-R, Figueras A, Lebrão ML et al (2010) Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging 27(9):759-770
17. Fokter N, Mozina M, Brvar M (2010) Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 122(3-4):81-88
18. Venturini CD, Engroff P, Ely LS et al (2011) Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clin São Paulo Braz 66(11):1867-1872
19. Guastaldi RBF, Reis AMM, Figueras A et al (2011) Prevalence of potential drug-drug interactions in bone marrow transplant patients. Int J Clin Pharm 33(6):1002-1009
20. Reis AMM, Cassiani SHDB (2011) Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clin São Paulo Braz 66(1):9-15
21. Lin C-F, Wang C-Y, Bai C-H (2011) Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study. Drugs Aging 28(3):219-225
22. Ismail M, Iqbal Z, Khattak M et al (2011) Prevalence, type and predictors of potential drug-drug interactions in pulmonology ward of a tertiary care hospital. Afr J Pharm Pharmacol 10(5):1303-1309
23. Teixeira JJV, Crozatti MTL, dos Santos CA et al (2012) Potential drug-drug interactions in prescriptions to patients over 45 years of Age in primary care, Southern Brazil. PLoS ONE 7(10):e47062
24. Ismail M, Iqbal Z, Khattak M et al (2012) Potential drug-drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res 11(2):289-296
25. Ismail M, Iqbal Z, Khattak M et al (2012) Potential drug-drug interactions in cardiology ward of a teaching hospital. HealthMED 6(5):1618-1624
26. Ba S, Admassie E, Hailu W et al (2013) Extent of poly-pharmacy, occurrence and associated factors of drug-drug interaction and potential adverse drug reactions in gondar teaching referral hospital, North West Ethiopia. J Adv Pharm Technol Res 4(4):183-189
27. Kashyap M, D'Cruz S, Sachdev A et al (2013) Drug-drug interactions and their predictors: results from Indian elderly inpatients. Pharm Pract 11(4):191-195
28. Riechelmann RP, Moreira F, Smaletz Ò et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286-290
29. Van Leeuwen RWF, Swart EL, Boven E et al (2011) Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 22(10):2334-2341
30. Van Leeuwen RWF, Brundel DHS, Neef C et al (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071-1078
31. Bacic-Vrca V, Marusic S, Erdeljic V et al (2010) The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 32(6):815-821
32. Hadjibabaie M, Badri S, Ataei S et al (2013) Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol 71(6):1619-1627
33. Vonbach P, Dubied A, Krähenbühl S et al (2008) Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 19(6):413-420
34. Lubinga SJ, Uwiduhaye E (2011) Potential drug-drug interactions on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors. Afr Health Sci 11(3):499-507
35. Guzek M, Zorina OI, Semmler A et al (2011) Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System): drug interactions in neurological inpatients. Pharmacoepidemiol Drug Saf 20(9):930-938
36. Chatsisvili A, Sapounidis I, Pavlidou G et al (2010) Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci 32(2):187-193
37. Zorina OI, Haueis P, Semmler A et al (2012) Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients: comparison of drug interaction screening programs. Pharmacoepidemiol Drug Saf 21(8):872-880
38. Zorina OI, Haueis P, Greil W et al (2013) Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients. Drug Saf 36(4):247-258
39. Smithburger PL, Kane-Gill SL, Seybert AL (2010) Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf 33(10):879-888
40. Ko Y, Tan S-LD, Chan A et al (2012) Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther 34(8):1696-1704
41. Smithburger PL, Kane-Gill SL, Seybert AL (2012) Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved: drug-drug interactions in the medical ICU. Int J Pharm Pract 20(6):402-408
42. Obreli Neto PR, Nobili A, Marusic S et al (2012) Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system. J Pharm Pharm Sci 15(2):344-354
43. Vonbach P, Dubied A, Beer JH et al (2007) Recognition and management of potential drug-drug interactions in patients on internal medicine wards. Eur J Clin Pharmacol 63(11):1075-1083
44. Bertoli R, Bissig M, Caronzolo D et al (2010) Assessment of potential drug-drug interactions at hospital discharge. Swiss Med Wkly. doi: 10.4414/smw.2010.13043
45. Taegtmeyer AB, Kullak-Ublick GA, Widmer N et al (2012) Clinical usefulness of electronic drug-drug interaction checking in the care of cardiovascular surgery inpatients. Cardiology 123(4):219-222
46. Marusic S, Bacic-Vrca V, Obreli Neto PR et al (2013) Actual drug-drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol 69(9):1717-1724
47. Smithburger PL, Kane-Gill SL, Benedict NJ et al (2010) Grading the severity of drug-drug interactions in the intensive care unit: a comparison between clinician assessment and proprietary database severity rankings. Ann Pharmacother 44(11):1718-1724
48. Dallenbach MF, Bovier PA, Desmeules J (2007) Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM 100(11):691-697
49. Brager R, Sloand E (2005) The spectrum of polypharmacy. Nurse Pract 30(6):44-50
50. Zarowitz BJ, Stebelsky LA, Muma BK et al (2005) Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy 25(11):1636-1645
51. Frazier SC (2005) Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 31(9):4-11
52. Fulton MM, Allen ER (2005) Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 17(4):123-132
53. Libby AM, Fish DN, Hosokawa PW et al (2013) Patient-level medication regimen complexity across populations with chronic disease. Clin Ther 35(4):385-398
54. Wongpoowarak W, Wongpoowarak P (2002) Unified algorithm for real-time detection of drug interaction and drug allergy. Comput Methods Programs Biomed 68(1):63-72. http://www.ncbi.nlm.nih.gov/pubmed/11886703
55. Barrons R (2004) Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61(4):380-385
56. Paciullo CA (2013) Book review: Stockley's Drug Interactions 10th ed. London, UK: Pharmaceutical Press; 2013. Ann Pharmacother 47(10): 1376